Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Amortization of Deferred Charges (2016 - 2023)

Historic Amortization of Deferred Charges for Fortress Biotech (FBIO) over the last 9 years, with Q3 2023 value amounting to $177000.0.

  • Fortress Biotech's Amortization of Deferred Charges fell 1194.03% to $177000.0 in Q3 2023 from the same period last year, while for Jun 2024 it was $177000.0, marking a year-over-year decrease of 6647.73%. This contributed to the annual value of $353000.0 for FY2023, which is 5415.58% down from last year.
  • As of Q3 2023, Fortress Biotech's Amortization of Deferred Charges stood at $177000.0, which was down 1194.03% from $85000.0 recorded in Q2 2023.
  • Over the past 5 years, Fortress Biotech's Amortization of Deferred Charges peaked at $221000.0 during Q1 2021, and registered a low of $85000.0 during Q2 2023.
  • In the last 4 years, Fortress Biotech's Amortization of Deferred Charges had a median value of $177000.0 in 2023 and averaged $173400.0.
  • In the last 5 years, Fortress Biotech's Amortization of Deferred Charges soared by 4733.33% in 2021 and then tumbled by 6046.51% in 2023.
  • Fortress Biotech's Amortization of Deferred Charges (Quarter) stood at $205000.0 in 2020, then dropped by 19.51% to $165000.0 in 2021, then fell by 8.48% to $151000.0 in 2022, then grew by 17.22% to $177000.0 in 2023.
  • Its Amortization of Deferred Charges was $177000.0 in Q3 2023, compared to $85000.0 in Q2 2023 and $91000.0 in Q1 2023.